QQQ   385.05 (-0.58%)
AAPL   192.32 (-0.57%)
MSFT   368.80 (-1.00%)
META   317.45 (-0.26%)
GOOGL   130.02 (-0.74%)
AMZN   144.52 (-1.61%)
TSLA   239.37 (+0.27%)
NVDA   455.03 (-2.28%)
NIO   7.76 (+4.44%)
BABA   71.51 (-1.20%)
AMD   116.82 (-1.32%)
T   16.95 (-1.57%)
F   10.69 (+0.85%)
MU   73.13 (-0.76%)
CGC   0.70 (+4.70%)
GE   119.81 (-0.35%)
DIS   91.50 (+0.78%)
AMC   6.79 (-3.28%)
PFE   28.81 (-1.00%)
PYPL   59.53 (+2.78%)
XOM   99.11 (-1.32%)
QQQ   385.05 (-0.58%)
AAPL   192.32 (-0.57%)
MSFT   368.80 (-1.00%)
META   317.45 (-0.26%)
GOOGL   130.02 (-0.74%)
AMZN   144.52 (-1.61%)
TSLA   239.37 (+0.27%)
NVDA   455.03 (-2.28%)
NIO   7.76 (+4.44%)
BABA   71.51 (-1.20%)
AMD   116.82 (-1.32%)
T   16.95 (-1.57%)
F   10.69 (+0.85%)
MU   73.13 (-0.76%)
CGC   0.70 (+4.70%)
GE   119.81 (-0.35%)
DIS   91.50 (+0.78%)
AMC   6.79 (-3.28%)
PFE   28.81 (-1.00%)
PYPL   59.53 (+2.78%)
XOM   99.11 (-1.32%)
QQQ   385.05 (-0.58%)
AAPL   192.32 (-0.57%)
MSFT   368.80 (-1.00%)
META   317.45 (-0.26%)
GOOGL   130.02 (-0.74%)
AMZN   144.52 (-1.61%)
TSLA   239.37 (+0.27%)
NVDA   455.03 (-2.28%)
NIO   7.76 (+4.44%)
BABA   71.51 (-1.20%)
AMD   116.82 (-1.32%)
T   16.95 (-1.57%)
F   10.69 (+0.85%)
MU   73.13 (-0.76%)
CGC   0.70 (+4.70%)
GE   119.81 (-0.35%)
DIS   91.50 (+0.78%)
AMC   6.79 (-3.28%)
PFE   28.81 (-1.00%)
PYPL   59.53 (+2.78%)
XOM   99.11 (-1.32%)
QQQ   385.05 (-0.58%)
AAPL   192.32 (-0.57%)
MSFT   368.80 (-1.00%)
META   317.45 (-0.26%)
GOOGL   130.02 (-0.74%)
AMZN   144.52 (-1.61%)
TSLA   239.37 (+0.27%)
NVDA   455.03 (-2.28%)
NIO   7.76 (+4.44%)
BABA   71.51 (-1.20%)
AMD   116.82 (-1.32%)
T   16.95 (-1.57%)
F   10.69 (+0.85%)
MU   73.13 (-0.76%)
CGC   0.70 (+4.70%)
GE   119.81 (-0.35%)
DIS   91.50 (+0.78%)
AMC   6.79 (-3.28%)
PFE   28.81 (-1.00%)
PYPL   59.53 (+2.78%)
XOM   99.11 (-1.32%)

NeuroMetrix Stock Price, News & Analysis (NASDAQ:NURO)

$3.72
+0.02 (+0.54%)
(As of 12/6/2023 ET)
Compare
Today's Range
$3.66
▼
$3.88
50-Day Range
$0.47
▼
$5.73
52-Week Range
$3.60
▼
$17.44
Volume
65,538 shs
Average Volume
10,793 shs
Market Capitalization
$4.00 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media

NURO stock logo

About NeuroMetrix Stock (NASDAQ:NURO)

NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico. Its primary marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system, a platform for the performance of nerve conduction studies. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.

NURO Stock Price History

NURO Stock News Headlines

December 5, 2023 | finance.yahoo.com
NeuroMetrix Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Showing that Quell® Improves Painful Symptoms of Chemotherapy Induced Peripheral Neuropathy (CIPN)
December 1, 2023 | americanbankingnews.com
NeuroMetrix (NASDAQ:NURO) Now Covered by StockNews.com
December 6, 2023 | Edge On The Street (Ad)
Americans Now Favor Gold Over Stocks as an Investment Vehicle
Americans now consider gold a better long-term investment than stocks for the first time since 2013. But physical gold requires storage and insurance, and gold mining stocks come with significant risks. Fortunately, investors have found a little-known way to benefit from gold that avoids many of these challenges.
November 30, 2023 | msn.com
OPEN, AMPE and NURO are among pre market gainers
November 20, 2023 | finanznachrichten.de
NeuroMetrix, Inc.: NeuroMetrix Announces One-for-Eight Reverse Stock Split
November 20, 2023 | finance.yahoo.com
NeuroMetrix Announces One-for-Eight Reverse Stock Split
October 30, 2023 | finance.yahoo.com
NeuroMetrix to Present at the Emerging Growth Conference on November 1, 2023
October 28, 2023 | finance.yahoo.com
NeuroMetrix, Inc. (NASDAQ:NURO) Q3 2023 Earnings Call Transcript
December 6, 2023 | Autonomix (Ad)
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology
Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
October 26, 2023 | msn.com
NeuroMetrix reports Q3 results
October 26, 2023 | finance.yahoo.com
NeuroMetrix Reports Q3 2023 Business Highlights
October 23, 2023 | finance.yahoo.com
NeuroMetrix, Inc. Announces Date for Third Quarter 2023 Business and Financial Highlights Conference Call
October 2, 2023 | finance.yahoo.com
NeuroMetrix and the National Fibromyalgia Association to Collaborate to Improve the Quality of Life for People Living with Fibromyalgia
September 28, 2023 | finance.yahoo.com
NeuroMetrix to Present at the Emerging Growth Conference on October 4, 2023
August 30, 2023 | finance.yahoo.com
NeuroMetrix to Present at the Emerging Growth Conference on September 6, 2023
August 28, 2023 | finance.yahoo.com
Is NeuroMetrix (NURO) Too Good to Be True? A Comprehensive Analysis of a Potential Value Trap
July 27, 2023 | finanznachrichten.de
NeuroMetrix, Inc.: NeuroMetrix Reports Q2 2023 Business Highlights
July 27, 2023 | finance.yahoo.com
NeuroMetrix Reports Q2 2023 Business Highlights
July 20, 2023 | finance.yahoo.com
NeuroMetrix, Inc. Announces Date for Second Quarter 2023 Business and Financial Highlights Conference Call
July 11, 2023 | finance.yahoo.com
NeuroMetrix Announces Sales Force Expansion for Quell Fibromyalgia
June 28, 2023 | finance.yahoo.com
Recent Publications Demonstrate Utility of DPNCheck® for Identifying High-Risk Diabetes Patients
June 7, 2023 | finance.yahoo.com
Diabetic Peripheral Neuropathy Screening That Includes DPNCheck® Predicts Mortality In A Prospective Clinical Study
May 31, 2023 | finance.yahoo.com
Quell® Demonstrates Encouraging Clinical Trial Results in Chemotherapy Induced Peripheral Neuropathy (CIPN)
May 16, 2023 | bizjournals.com
Autonomous delivery vehicle startup Nuro is cutting staff and production to focus on R&D
May 3, 2023 | finance.yahoo.com
NeuroMetrix Reports Q1 2023 Financial Results
April 28, 2023 | finance.yahoo.com
NeuroMetrix, Inc. Announces Date for First Quarter 2023 Financial Results Conference Call
March 21, 2023 | finance.yahoo.com
NeuroMetrix to Exhibit Quell® Fibromyalgia and Present New Clinical Data at the American Academy of Pain Medicine 2023 Annual Meeting
See More Headlines
Receive NURO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NeuroMetrix and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
10/26/2023
Today
12/06/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/22/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NURO
CUSIP
N/A
CIK
1289850
Web
www.neurometrix.com
Phone
(781) 890-9989
Fax
302-636-5454
Employees
27
Year Founded
1996

Profitability

EPS (Most Recent Fiscal Year)
($5.52)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-4,420,000.00
Net Margins
-86.64%
Pretax Margin
-86.64%
Return on Equity
-25.71%
Return on Assets
-24.14%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
16.43
Quick Ratio
15.11

Sales & Book Value

Annual Sales
$6.43 million
Price / Sales
0.62
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$24.09 per share
Price / Book
0.15

Miscellaneous

Outstanding Shares
1,074,000
Free Float
993,000
Market Cap
$3.98 million
Optionable
Not Optionable
Beta
2.25

Social Links

The Best High-Yield Dividend Stocks for 2023 Cover
The Best High-Yield Dividend Stocks for 2023

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

Key Competitors

View All Competitors














NURO Stock Analysis - Frequently Asked Questions

How have NURO shares performed in 2023?

NeuroMetrix's stock was trading at $11.92 on January 1st, 2023. Since then, NURO shares have decreased by 68.9% and is now trading at $3.71.
View the best growth stocks for 2023 here.

Are investors shorting NeuroMetrix?

NeuroMetrix saw a drop in short interest in November. As of November 15th, there was short interest totaling 4,600 shares, a drop of 84.4% from the October 31st total of 29,400 shares. Based on an average trading volume of 6,500 shares, the days-to-cover ratio is presently 0.7 days. Approximately 0.4% of the company's shares are sold short.
View NeuroMetrix's Short Interest.

When is NeuroMetrix's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 22nd 2024.
View our NURO earnings forecast.

How were NeuroMetrix's earnings last quarter?

NeuroMetrix, Inc. (NASDAQ:NURO) issued its earnings results on Thursday, October, 26th. The medical device company reported ($1.68) earnings per share for the quarter. The medical device company had revenue of $1.20 million for the quarter. NeuroMetrix had a negative net margin of 86.64% and a negative trailing twelve-month return on equity of 25.71%.

When did NeuroMetrix's stock split?

NeuroMetrix shares reverse split on Wednesday, November 22nd 2023. The 1-8 reverse split was announced on Monday, November 20th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, November 21st 2023. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.

What is Shai N. Gozani's approval rating as NeuroMetrix's CEO?

10 employees have rated NeuroMetrix Chief Executive Officer Shai N. Gozani on Glassdoor.com. Shai N. Gozani has an approval rating of 57% among the company's employees. This puts Shai N. Gozani in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of NeuroMetrix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NeuroMetrix investors own include Merit Medical Systems (MMSI), Palatin Technologies (PTN), Citigroup (C), Salesforce (CRM), Nokia Oyj (NOK), ReWalk Robotics (RWLK), Aurora Cannabis (ACB), Advanced Micro Devices (AMD) and Vaxart (VXRT).

How do I buy shares of NeuroMetrix?

Shares of NURO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:NURO) was last updated on 12/6/2023 by MarketBeat.com Staff

My Account -